BA-Merrill Lynch 18/09/2009 1 Buy, Medium Risk $39.35 12.6%
Baxter has guided for 7-9% revenue growth over the next 5 years for its BioScience division, which is equivalent to CSL's Behring.
The broker notes this view pretty much matches what CSL is expecting. The broker thinks thereport also supports the broker's view that unmet clinical need remains high in developed and middle markets, meaning more growth will come from markets outside the US
The other good bit is that the broker expects to see further demand in these non-US markets in lines that aren't being sold there yet. No change to Buy, target or forecasts.
latest rating
-
- There are more pages in this discussion • 45 more messages in this thread...
You’re viewing a single post only. To view the entire thread just sign in or Join Now (FREE)
Add CSL (ASX) to my watchlist
 (20min delay)
|
|||||
|
Last
$293.70 |
Change
1.690(0.58%) |
Mkt cap ! $141.9B | |||
| Open | High | Low | Value | Volume |
| $293.55 | $294.28 | $292.12 | $189.1M | 644.4K |
Buyers (Bids)
| No. | Vol. | Price($) |
|---|---|---|
| 2 | 956 | $293.67 |
Sellers (Offers)
| Price($) | Vol. | No. |
|---|---|---|
| $293.70 | 763 | 1 |
View Market Depth
| Last trade - 16.10pm 25/06/2024 (20 minute delay) ? |
| CSL (ASX) Chart |